表达 IL-21 的工程化 NK 细胞对抗胶质母细胞瘤干细胞，有可能带来一种新的治疗方法。 Engineered NK cells expressing IL-21 combat glioblastoma stem cells, potentially leading to a new therapeutic approach.

德克萨斯大学MD安德森癌症中心的研究人员发现,天然杀手细胞 (NK) 经过设计以表达双白素-21 (IL-21) 细胞,在体外和体内都能有效地对抗类似质母细胞的干细胞. Researchers at the University of Texas MD Anderson Cancer Center discovered that natural killer (NK) cells, engineered to express interleukin-21 (IL-21), effectively combat glioblastoma stem cell-like cells both in vitro and in vivo. 他们的研究结果可能导致对激进的脑癌采取新的治疗方法,脑癌的治疗选择有限,存活率低。 Their findings could lead to a new therapeutic approach for the aggressive brain cancer, which has limited treatment options and poor survival rates. 预计今年晚些时候将开始临床试验,以便在血浆瘤患者中应用IL-21工程型纳戈尔诺-卡拉巴赫细胞。 A clinical trial is anticipated to begin later this year for the application of IL-21 engineered NK cells in glioblastoma patients.